Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Background Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like
ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with …

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …

Background Few options exist for treatment of patients with small-cell lung cancer (SCLC)
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic …

Background Treatments for small-cell lung cancer (SCLC) after failure of platinum-based
chemotherapy are limited. We assessed safety and activity of nivolumab and nivolumab plus …

Purpose: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to
first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab …

Background Patients with relapsed small-cell lung cancer (SCLC) have few treatment
options and dismal survival. Phase I/II data show activity of nivolumab in previously treated …

The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large
cell neuroendocrine carcinoma (LCNEC), remain among the most deadly malignancies …

Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP
have modest single-agent activity. We performed a phase I/II trial of combination olaparib …